Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Molecular basis of antifungal drug resistance in yeasts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early IL-2 treatment of mice with Pseudomonas aeruginosa pneumonia induced PMN-dominating response and reduced lung pathology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Cystic fibrosis (CF) patients are at risk of acquiring chronic Pseudomonas aeruginosa lung infections. The biofilm mode of growth of P. aeruginosa induces tolerance to antibiotics and the host response; accordingly, treatment failure occurs. Supplemental azithromycin has proven beneficial in CF owing to potential immunomodulatory mechanisms. Clinical studies have demonstrated a reduction in exacerbations in CF patients by avian IgY anti-Pseudomonas immunotherapy. We hypothesise that azithromycin pre-treatment could potentiate the observed anti-Pseudomonas effect of IgY opsonisation in vivo. Evaluation of phagocytic cell capacity was performed using in vitro exposure of azithromycin pre-treated human polymorphonuclear neutrophils to IgY opsonised P. aeruginosa PAO3. A murine lung infection model using nasal planktonic P. aeruginosa inoculation and successive evaluation 24 h post-infection was used to determine lung bacteriology and subsequent pulmonary inflammation. Combined azithromycin treatment and IgY opsonisation significantly increased bacterial killing compared with the two single-treated groups and controls. In vivo, significantly increased bacterial pulmonary elimination was revealed by combining azithromycin and IgY. A reduction in the inflammatory markers mobiliser granulocyte colony-stimulating factor (G-CSF), macrophage inflammatory protein 2 (MIP-2) and interleukin 1 beta (IL-1β) paralleled this effect. Combination of azithromycin and anti-Pseudomonas IgY potentiated the killing and pulmonary elimination of P. aeruginosa in vitro and in vivo. The augmented effect of combinatory treatment with azithromycin and IgY constitutes a potential clinical application for improving anti-Pseudomonas strategies.

OriginalsprogEngelsk
Artikelnummer106213
TidsskriftInternational Journal of Antimicrobial Agents
Vol/bind57
Udgave nummer1
Sider (fra-til)106213
ISSN0924-8579
DOI
StatusUdgivet - 1 jan. 2021

Bibliografisk note

Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

ID: 61371758